Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 2Thoracic 1

Conditions

Prostatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 909Carboplatin 787pembrolizumab 744Paclitaxel 742Cisplatin 709Bevacizumab 706Gemcitabine 619Docetaxel 579Rituximab 548Radiotherapy 541Dexamethasone 511Nivolumab 488Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 358Pemetrexed 337Cytarabine 335Oxaliplatin 333Lenalidomide 328Prednisone 326fludarabine phosphate 316Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 276

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Has results × Clinical Trials, Phase II as Topic × Clear all
NCT01171898 2026-05-11

Safety, Pharmacokinetic and Proof-of-Concept Study of ARN-509 (Apalutamide) in Castration-Resistant Prostate Cancer (CRPC)

Aragon Pharmaceuticals, Inc.

Phase 1/2 Completed
127 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT02382406 2023-05-23

Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC

Hoosier Cancer Research Network

Phase 1/2 Terminated
46 enrolled 24 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00547339 2022-12-07

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

University of Texas Southwestern Medical Center

Phase 1/2 Completed
94 enrolled 14 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡